Stifel Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $30
Stifel analyst Stephen Willey maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and adjusts the target price from $27 to $30.According to TipRanks data, the analyst has a success rate of 42.1
Stifel Nicolaus Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
JPMorgan Adjusts Price Target on Nurix Therapeutics to $34 From $31, Maintains Overweight Rating
Nurix Therapeutics (NRIX) has an average outperform rating and a price target range of $15 to $35, according to analysts polled by Capital IQ.Price: 23.45, Change: -0.37, Percent Change: -1.55
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 42.14% JP Morgan $31 → $34 Maintains Overweight 07/15/2024 29.6% Barclays $20 → $31 Maintains
Nurix Therapeutics Is Maintained at Overweight by Barclays
Nurix Therapeutics Is Maintained at Overweight by
Express News | Nurix Therapeutics Inc. : Morgan Stanley Raises Target Price to $15.00 From $14.00
J.P. Morgan Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $34
J.P. Morgan analyst Eric Joseph maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and adjusts the target price from $31 to $34.According to TipRanks data, the analyst has a success rate of 50
Barclays Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $31
Barclays analyst Peter Lawson maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 44.1% and
Nurix Therapeutics: A Strong Buy on Robust Clinical Data and Strategic Financial Partnerships
Express News | Nurix Therapeutics Inc : JP Morgan Raises Target Price to $34 From $31
Barclays Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)
We're Not Very Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. Indeed, Nurix Therapeutics (NASDAQ:NRIX) stock is up 144% in the last year, providing strong gains for shareholders.
Nurix Therapeutics: Promising Drug Pipeline Amid Long-Term Market Prospects and Clinical Risks
Oppenheimer Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $25
Oppenheimer analyst Matthew Biegler maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 32.6%
Nurix Therapeutics Is Maintained at Outperform by RBC Capital
Nurix Therapeutics Is Maintained at Outperform by RBC
Needham Adjusts Price Target on Nurix Therapeutics to $29 From $31, Maintains Buy Rating
Nurix Therapeutics (NRIX) has an average outperform rating and price target range of $14 to $35, according to analysts polled by Capital IQ.Price: 22.18, Change: +0.15, Percent Change: +0.68
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $27
RBC Capital analyst Gregory Renza maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and adjusts the target price from $26 to $27.According to TipRanks data, the analyst has a success rate
Wells Fargo Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $32
Wells Fargo analyst Derek Archila maintains $Nurix Therapeutics(NRIX.US)$ with a buy rating, and adjusts the target price from $27 to $32.According to TipRanks data, the analyst has a success rate
Express News | Nurix Therapeutics, Inc. : Wells Fargo Raises Target Price to $32 From $27
Nurix Therapeutics (NRIX) Receives a Buy From Wells Fargo